Equities

Solventum Corp

Solventum Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)72.38
  • Today's Change0.245 / 0.34%
  • Shares traded230.47k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 16:43 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform0
Hold5
Sell1
Strong Sell0

Share price forecast in USD

The 4 analysts offering 12 month price targets for Solventum Corp have a median target of 62.00, with a high estimate of 75.00 and a low estimate of 54.00. The median estimate represents a -14.04% decrease from the last price of 72.13.
High4.0%75.00
Med-14.0%62.00
Low-25.1%54.00

Earnings history & estimates in USD

On Aug 08, 2024, Solventum Corp reported 2nd quarter 2024 earnings of 1.56 per share.
Average growth rate-25.00%
More ▼

Revenue history & estimates in USD

Solventum Corp had 2nd quarter 2024 revenues of 2.08bn. This bettered the 2.05bn consensus of the 3 analysts covering the company. The same period last year the company did not report revenues.
Average growth rate+3.22%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.